SEC Company Response from BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Nov 9, 2011
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: Nov. 9, 2011 · CIK: 0001137883 · Accession: 0001144204-11-062400
AI Filing Summary & Sentiment
Reasoning
Referenced dates: October 26, 2011
Letter
Securities and Exchange Commission (Mail Stop 4561) Brainstorm Cell Therapeutics Inc. Form 10-K for the Fiscal Year ended December 31, 2010 Filed March 31, 2011 File No. 0-54365
Re:
Dear Mr. Rosenberg:
We are in receipt of the letter dated October 26, 2011 from the Staff of the U.S. Securities and Exchange Commission containing comments on our above-captioned filing (the “Comment Letter”). We note that the Comment Letter requests us either to respond within 10 business days or to tell the Staff when we will provide a response.
We are requesting a waiver from the Office of the Chief Accountant for one of the required audit reports. We anticipate that we will receive an answer from the Office of the Chief Accountant within 10 business days. We hereby request an extension for submitting a response to the Comment Letter. We will file a response to the Comment Letter shortly after receiving an answer from the Office of the Chief Accountant.
If you have any questions with regards to this request please contact the undersigned at +972 3 923 6384 or Thomas Rosedale of BRL Law Group LLC at (617) 399-6935.
Very truly yours,
/s/ Liat Sossover
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
November 9, 2011
Jim B. Rosenberg
Senior Assistant Chief Accountant
Securities and Exchange Commission (Mail Stop 4561)
100 F Street, N.E.
Washington, D.C. 20549
Re:
Brainstorm Cell Therapeutics Inc.
Form 10-K for the Fiscal Year ended December 31, 2010
Filed March 31, 2011
File No. 0-54365
Dear Mr. Rosenberg:
We are in receipt of the letter dated October 26, 2011 from the Staff of the U.S. Securities and Exchange Commission containing comments on our above-captioned filing (the “Comment Letter”). We note that the Comment Letter requests us either to respond within 10 business days or to tell the Staff when we will provide a response.
We are requesting a waiver from the Office of the Chief Accountant for one of the required audit reports. We anticipate that we will receive an answer from the Office of the Chief Accountant within 10 business days. We hereby request an extension for submitting a response to the Comment Letter. We will file a response to the Comment Letter shortly after receiving an answer from the Office of the Chief Accountant.
If you have any questions with regards to this request please contact the undersigned at +972 3 923 6384 or Thomas Rosedale of BRL Law Group LLC at (617) 399-6935.
Very truly yours,
/s/ Liat Sossover
Liat Sossover
Copy to: Thomas B. Rosedale, Esq.
_______________________________________________________________________________________________________________________________________________
BrainStorm Cell Therapeutics Inc.
605 Third Avenue, 34th Floor
New York NY 10158
Tel: (212) 557-9000
BrainStorm Cell Therapeutics Ltd.
12 Bazel St., POB 10019 Kiryat Aryeh,
Petach Tikva, Israel 49001
Tel: (972) 3.923.6384
Fax: (212) 286-1884
E-mail: info@brainstorm-cell.com